How many “different” types of prostate cancer are there?

This, of course, is a rhetorical question. We really have no good idea how many “different” types of prostate cancer there are. And so what we are really dealing with here is how we are going to sub-classify prostate cancers in the future in order to treat them most appropriately at the earliest relevant stage of development. … READ MORE …

Important new standards for data collection in studies of advanced prostate cancer

Recently we noted that Morgans et al. had published information about a proposed, standardized set of patient-centered outcomes data for advanced prostate cancer that would facilitate cross-comparison of data from the many trials that take now place in the management of TxNxM+ prostate cancer. … READ MORE …

Management of incident prostate cancer on active surveillance

Back in the dim and distant past (i.e., the 1980s and the very early 1990s, before PSA testing was widespread) one of the most common ways to find early stage prostate cancer was as an incidental consequence of the conduct of a transurethral resection of the prostate (a “TURP”) to treat symptoms of urinary tract obstruction. … READ MORE …

Chemo + ADT + RT: no benefit after 10 years

Earlier this month, we looked at the evidence of benefit for adding chemotherapy to androgen deprivation therapy (ADT) + radiation therapy (RT) for high-risk prostate cancer (see “Docetaxel with radiation in prostate cancer treatment”). … READ MORE …

Survival benefit of dose escalation for higher risk patients

As discussed in a previous article, there is a seeming discrepancy between the findings of Kalbasi et al. and RTOG 0126, at least for intermediate-risk patients. … READ MORE …

New trial of investigational immunotherapy in men on active surveillance

There appears to be a high degree of confidence that Barvarian Nordic’s Prostvac will show positive results in the ongoing Phase III clinical trial in men with metastatic, castration-resistant prostate cancer. An early stage trial has now been initiated among men with much less advanced disease disease. … READ MORE …

The cost of drugs for the treatment of cancer — in the pressure cooker

According to an announcement this morning from The Mayo Clinic, a group of 118 leading cancer experts has drafted proposals for reducing the high cost of cancer drugs and voiced support for a patient-based grassroots movement demanding action on the issue. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,342 other followers